Leads Biolabs to Present at 2024 ASCO Annual Meeting

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the world's premier oncology conference, will be hosted in Chicago from May 31 to June 4, 2024. The event gathers the latest research breakthroughs in the field. Leads Biolabs will present clinical data from four of its innovative programs at the meeting, including one oral presentation, two posters, and an online publication. These will cover advancements in treating nasopharyngeal cancer (NPC), extrapulmonary neuroendocrine carcinoma (EP-NEC), hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC).

In the oral presentation, Leads Biolabs will highlight LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, which has shown significant efficacy in phase I/II trials for patients with advanced malignant tumors and neuroendocrine carcinoma. The presentation, scheduled for June 2, 2024, from 4:30 PM to 6:00 PM CDT, will focus on the safety and promising antitumor effects observed in the study. LBL-024 received Investigational New Drug (IND) approvals from the FDA and NMPA in 2021 and has recently been approved for a pivotal study in China. The therapy has demonstrated impressive results, particularly in EP-NEC patients who have failed prior chemotherapy treatments, showing superior efficacy compared to historical data.

The first poster presentation will discuss LBL-007, an anti-LAG-3 antibody used in combination with the anti-PD-1 antibody Tislelizumab, with or without chemotherapy, for treating advanced nasopharyngeal cancer and other malignant tumors. This phase Ib/II study has demonstrated that the combination therapy is well-tolerated and effective, especially in previously untreated NPC patients. The poster will be presented on June 2, 2024, from 9:00 AM to 12:00 PM CDT.

Another poster will detail the clinical data on LBL-015, a bifunctional antibody fusion protein targeting PD-1 and TGF-βRII. This antibody aims to reverse immunosuppression in the tumor microenvironment and boost immune responses, thereby inhibiting tumor growth and metastasis. The phase I study has shown a good safety profile and encouraging efficacy in patients with advanced solid tumors. This poster will be presented on June 1, 2024, from 9:00 AM to 12:00 PM CDT.

An online publication will focus on LBL-019, a monoclonal antibody targeting TNFR2. The study has shown that LBL-019 is well-tolerated and demonstrates preliminary efficacy in patients with advanced malignant tumors. The publication will be available on May 23, 2024, at 5:00 PM EDT.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, emphasized the significance of these presentations. He highlighted the outstanding efficacy of LBL-024 compared to previous treatments, which supports its accelerated development. The promising data on LBL-007 in combination with Tislelizumab, gemcitabine, and cisplatin for NPC also pave the way for further pivotal studies. Dr. Cai underscored Leads Biolabs' commitment to innovative and efficient clinical development strategies aimed at bringing effective therapies to market quickly, reflecting the company's dedication to addressing patient needs and delivering clinical value.